Investigating a targeted treatment for hypertension in Black individuals with a specific genetic risk
Role of LSD1 in Hypertension in Blacks
This study is testing whether a targeted blood pressure medication called eplerenone works better than a standard treatment for Black individuals with a specific genetic risk for high blood pressure.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 17 Years and up |
| Sex | All |
| Sponsor | Brigham and Women's Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT04840342 on ClinicalTrials.gov |
What this trial studies
This study examines the effectiveness of a genetically-driven anti-hypertensive treatment using eplerenone compared to a standard treatment with amlodipine in Black individuals who carry the LSD1 risk allele. It aims to determine if eplerenone can achieve greater reductions in blood pressure and reduce renal injury over a 12-week period. The study will enroll 56 participants in a randomized, double-blind, active-controlled design, assessing 24-hour ambulatory systolic blood pressure changes. Participants will receive either eplerenone or amlodipine, with dose adjustments based on blood pressure readings.
Who should consider this trial
Good fit: Ideal candidates are Black individuals aged over 17 who are carriers of the rs587168 allele and have untreated or treated hypertension.
Not a fit: Patients with known cardiac disease, renal or circulatory issues, diabetes, or secondary hypertension may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective hypertension management and reduced renal damage in a specific subset of patients.
How similar studies have performed: While this approach is novel in its genetic targeting, similar studies have shown promise in personalized medicine for hypertension management.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * untreated as well as currently treated hypertensives * rs587168 allele carriers * not on more than two anti-hypertensives * normal renal, metabolic, electrolyte, and CBC laboratory tests * self-identified Black race * age \>17 yrs. Exclusion Criteria: * known cardiac disease other than HTN * renal, circulatory or neurologic diseases * diabetes * smoking * secondary HTN as indicated by history, physical examination or screening blood and urine tests * smoking * any drug therapy, except for anti-hypertensives and stable thyroid medication replacement
Where this trial is running
Boston, Massachusetts
- Brigham and Women's — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Andrea Haas, MD — Brigham and Women's
- Study coordinator: Andrea Haas, MD
- Email: ahaas2@bwh.harvard.edu
- Phone: 6177325666
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.